肺癌
医学
免疫疗法
临床试验
肿瘤科
个性化
内科学
癌症
重症监护医学
计算机科学
万维网
作者
Sarah Soyeon Oh,George N Botros,Milan Patel,Missak Haigentz,Eshan U. Patel,Iaonnis Kontopidis,John Langenfeld,Matthew P. Deek,Salma K. Jabbour
标识
DOI:10.1016/j.hoc.2023.02.007
摘要
Consolidation immunotherapy after concurrent chemoradiation has improved five-year survival rates in unresectable, locally advanced lung cancer, but disease progression and treatment personalization remain challenges. New treatment approaches with concurrent immunotherapy and consolidative novel agents are being investigated and show promising efficacy data, but at the risk of additive toxicity. Patients with PD-L1 negative tumors, oncogenic driver mutations, intolerable toxicity, or limited performance status continue to require innovative therapies. This review summarizes historical data that galvanized new research efforts, as well as ongoing clinical trials that address the challenges of current therapeutic approaches for unresectable, locally advanced lung cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI